PET in the management of urologic malignancies
Section snippets
Prostate cancer
Carcinoma of the prostate is the second most common cause of death from cancer among men in America. The incidence of disease is likely to increase with improved detection and public awareness. Optimal treatment of this cancer depends on the accurate staging of the disease at the time of presentation. Localized primary or recurrent prostate cancer can be treated with radical prostatectomy [5]. Chemotherapy, immunotherapy, or hormonal therapies are the most frequent choices of treatment of
Testicular cancer
Testicular cancer is the most common tumor of young men and its incidence is increasing [35]. Seminoma and nonseminoma germ cell tumors (NSGCTs) have different biologic behaviors. Most patients with minimal metastatic disease can be cured with chemotherapy. NSGCTs with stage I disease does not require chemotherapy and can be followed-up clinically for progression.
Diagnosis and staging
Despite significant uptake and excretion through the kidneys, FDG has been used in the diagnosis and management of renal cell carcinoma (RCC). Bachor et al [53] studied 29 patients with solid renal masses and found that PET was positive in 20 (77%) of 26 patients of RCC. PET was false-negative in the remaining six patients; and it was false-positive in an angiomyolipoma, a pericytoma, and a pheochromocytoma. Ramdave et al [54] evaluated the accuracy of FDG-PET for staging and management of 17
Bladder cancer
Physiologic excretion of FDG in urine results in much difficulty in detecting lesions in the bladder and adjacent lymph nodes. FDG-PET has a limited use in diagnosis and management of bladder cancer. Kosuda et al [60] studied 12 patients with FDG-PET for the evaluation of recurrent or residual disease. PET identified 100% (17 of 17) of distant metastases (lung, bones, and remote lymph nodes) and 67% (2 of 3) of local lymph nodes. Heicappell et al [14] also had similar detection rate of 67% for
Summary
FDG-PET has a limited role in the diagnosis of prostate cancer mainly because of the low uptake of FDG in the tumor and normal excretion of FDG through urine. FDG-PET has shown some promise in the assessment of lymph nodes and bone metastases. There is a large degree of variability when FDG-PET is compared with bone scintigraphy. New C11-labeled radiotracers (acetate, choline, and methionine) have shown promising initial results but further studies are required to determine their role in such
References (61)
- et al.
Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
J Urol
(1999) - et al.
5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
J Urol
(1994) - et al.
Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose
J Urol
(1996) - et al.
Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer
Urology
(2001) - et al.
Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer
Mol Imaging Biol
(2002) - et al.
Detection of bony metastases of androgen-independent prostate cancer by PET-FDG
Nucl Med Biol
(1996) - et al.
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer
Urology
(2002) - et al.
Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer
Mol Imaging Biol
(2003) - et al.
Visualization of prostate cancer with 11C-choline positron emission tomography
Eur Urol
(2002) - et al.
Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography
J Urol
(2003)
Differential Metabolism and pharmacokinetics of L-[1-(11)C]-methionine and 2-[(18)F] fluoro-2-deoxy-D-glucose (FDG) in androgen independent prostate cancer
Clin Positron Imaging
Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors
Urology
Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors
Urology
Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients
Urology
Early detection of relapse after treatment for metastatic germ cell tumour of the testis: an exercise in medical audit
Clin Oncol (R Coll Radiol)
Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma
J Urol
FDG PET characterization of renal masses: preliminary experience
Clin Radiol
Positron emission tomography imaging in evaluation of cancer patients
Indian J Cancer
Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy
Eur Urol
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse
J Nucl Med
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
N Engl J Med
The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer
Jpn J Clin Oncol
Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer
BJU Int
Carbon-11-acetate PET imaging in renal disease
J Nucl Med
Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer
Eur J Nucl Med Mol Imaging
Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose
Eur Urol
Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer
BJU Int
Detecting metastatic pelvic lymph nodes by 18Fâ2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer
Urol Int
Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients
Eur J Nucl Med Mol Imaging
Comparison and discrepancy of 18Fâ2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases
Anticancer Res
Cited by (61)
Preclinical Study on GRPR-Targeted <sup>68</sup>Ga-Probes for PET Imaging of Prostate Cancer
2016, Bioconjugate ChemistryACR appropriateness criteria prostate cancer - Pretreatment detection, staging, and surveillance
2013, Journal of the American College of RadiologyCitation Excerpt :Clinical evidence is accumulating at research centers, but as of this writing, CMS has not granted coverage at nonresearch sites. The role of PET and PET/CT in the staging workup of newly diagnosed and recurrent prostate cancer is still being evaluated [102-105]. It has the potential to play an important role in detecting early metastatic spread and monitoring posttherapy response.
<sup>18</sup>F-FDG PET/CT with retrograde filling of the urinary bladder in the assessment of malignant pelvic disease
2011, Revista Espanola de Medicina NuclearFDG PET/CT in Prostate Metastasis from Gastric Cancer
2022, Clinical Nuclear Medicine